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A B S T R A C T
Background. The fibroblast growth factor 23 (FGF23) response to phosphate load is suppressed in adiponectin gene null mice and substantially amplified in mice overexpressing the same gene and vitamin D receptor (VDR) activation markedly enhances FGF23 gene expression. Methods. We performed an analysis of the static (baseline adiponectin levels) and dynamic (fluctuations in adiponectin levels) interactions of serum adiponectin with the FGF23 response to paricalcitol and placebo in the setting of a double-blind, randomized clinical trial in chronic kidney disease (CKD) patients (NCT01680198). Results. As compared with placebo, VDR activation by paricalcitol markedly increased serum FGF23 levels (P < 0.001), and such an increase was amplified in patients in the 4th adiponectin quartile as compared with other quartiles (P ¼ 0.009) while no such an effect was noted in the placebo group (P ¼ 0.49). Both baseline adiponectin (P for interaction ¼ 0.009) and fluctuations in adiponectin levels following paricalcitol and placebo (P for interaction ¼ 0.003) strongly modified the difference in the FGF23 response to these treatments. These interactions were specific because no similar effect modification by other factors with the FGF23 response to VDR activation was found. Furthermore, in a global correlation analysis, adiponectin and FGF23 were interrelated independent of the estimated glomerular filtration rate and other potential confounders (b ¼ 0.22, P ¼ 0.003). Conclusions. Adiponectin is a strong modifier of the FGF23 response to VDR activation in CKD patients. The adiponectin-FGF23 link discovered in genetically engineered mice is of mechanistic relevance in the FGF23 response to VDR activation in CKD patients.
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Vitamin D is a fundamental micronutrient for human health because it interferes with a variety of major physiological functions from the regulation of bone-mineral metabolism and skeletal health to the immune response and glucose and adipose tissue metabolism [1] . Adipocytes store vitamin D and this vitamin regulates several key cellular activities by interacting with membrane receptors, adaptor molecules and nuclear co-regulator proteins [2] . Apart from vitamin D, evidence is emerging that there is a crosstalk between the energy storage organ, the adipose tissue and the skeleton. Indeed, mice overexpressing the most abundant adipose tissue protein, adiponectin, exhibit a substantially enhanced fibroblast growth factor 23 (FGF23) response to phosphate load as compared with wild-type and adiponectin knockout mice [3] . Furthermore, vitamin D receptor (VDR) activation markedly upregulates FGF23 gene expression [4] and substantially increases circulating levels of FGF23 in healthy subjects with vitamin D deficiency [5] and in chronic kidney disease (CKD) patients [6, 7] . Alterations in circulating levels of the active form of vitamin D (1,25-OH vitamin D) [8] , adiponectin [9] and FGF23 [10] are hallmarks in CKD patients. However, until now the hypothesis that the mutual interrelationships between vitamin D, adiponectin and FGF23 in these patients are of mechanistic relevance rests solely on purely descriptive data in the general population [11] [12] [13] . If these links are functional in nature, VDR activation is not only expected to increase FGF23 levels, but also that such an increase is modified by adiponectin. To investigate this hypothesis, we performed a post hoc analysis in the biological database of a double-blind, randomized controlled clinical trial, the Paracalcitol and Endothelial Function in Chronic Kidney Disease Patients (the PENNY study); ClinicalTrials.gov identifier NCT01680198 in patients with Stage 3 or 4 CKD [7] . In this analysis we tested the static and dynamic interaction of adiponectin with the FGF23 response to VDR activation by paricalcitol.
M A T E R I A L S A N D M E T H O D S
The study protocol was approved by the ethics committee of our institution. A written, informed consent was obtained from each participant.
Patients
The protocol of the PENNY trial and the corresponding Consolidated Standards of Reporting Trials (CONSORT) flow diagram are detailed in a previous paper describing the main results of the study [7] . Briefly, PENNY is a double-blind, randomized, parallel group trial (ClinicalTrials.gov identifier NCT01680198) that enrolled 88 patients with CKD Stage 3 or 4. Inclusion criteria were age 18-80 years, parathyroid hormone (PTH) > 65 pg/mL, serum total calcium between 2.2 and 2.5 mmol/L and phosphate levels between 0.97 and 1.5 mmol/L. Exclusion criteria were treatment with vitamin D compounds or anti-epileptic drugs and the presence of neoplasia, symptomatic cardiovascular disease or liver disease. Patients who met the inclusion criteria were randomized (1:1) to receive 2 mg paricalcitol once daily or matching placebo for 12 weeks after a 2-week run-in. Measurements of relevant variables in PENNY were made at baseline and after 12 weeks of treatment with paricalcitol or placebo. The dose of paricalcitol was adjusted on the basis of serum PTH and calcium and the maximum dose allowed was 2 mg daily. No vitamin D compounds were allowed during the trial. The demographic, clinical and biochemical data of the two study arms are listed in Table 1 .
Laboratory measurements
Serum calcium, phosphate, glucose and lipids were measured in the routine clinical pathology laboratory at our Institution. Serum creatinine was measured by the Roche enzymatic, isotope dilution mass spectrometry (IDMS) calibrated method and serum cystatin C by the Siemens Dade Behring kit and the glomerular filtration rate (GFR) was calculated by the Chronic Kidney Disease Epidemiology Collaboration creatinine-cystatin formula [14] . Serum PTH was measured by immunoradiometric assay (DiaSorin, Stillwater, MN, USA) as well as adiponectin (Linco Research, St Charles, MO, USA), 25-OH vitamin D and 1,25-OH vitamin D (Immunodiagnostic Systems, Boldon, UK). Serum intact FGF23 was measured by an enzyme-linked immunosorbent assay kit (Kainos Laboratories, Bunkyo, Tokyo, Japan). Serum samples were available in all patients (no missing sample) and were stored frozen at À80 C, without freeze-thaw cycles, until measurements of biomarkers were performed.
Statistical analysis
Data are reported as mean 6 standard deviation (SD; normally distributed data), median and interquartile range (IQR; non-normally distributed data) or as percent frequency and comparisons between groups were made by independent t-test, Mann-Whitney test or chi-square test. The relationship between two variables was tested by Pearson's correlation coefficient (on log 10 -transformed data, when appropriate). The global relationship between repeated adiponectin and FGF23 measurements over time was investigated by weighting the regression line by the patient's identifier and adjusting for the allocation arm, estimated GFR (eGFR), age, gender and body mass index (BMI). In this weighted linear regression analysis, data were expressed as standardized regression coefficient (b) and P-value. The effect of paricalcitol on adiponectin and FGF23 after 12 weeks of treatment was analysed by applying the generalized linear model (GLM). Differences in risk factors at baseline (P 0.10) not controlled by randomization, namely the eGFR, FGF23 and calcium carbonate treatment, were accounted for by introducing the same risk factors in the GLM. The effect size of paricalcitol on the outcome measures in this study was summarized by the generalized eta-squared, as recommended by Bakeman [15] . The static and dynamic effect modification by baseline adiponectin and adiponectin fluctuations on the FGF23 response (dependent variable) to treatments (paricalcitol versus placebo) was tested in a model including allocation arm, baseline adiponectin (or adiponectin fluctuations) and their interaction term as well as baseline eGFR, calcium carbonate and FGF23 (i.e. variables that differed with a P-value 0.10 at baseline between the two allocation arms). To minimize the problem of alpha inflation due to multiple testing, only the interactions with P < 0.01 were considered statistically significant. Data analysis was performed using SPSS for Windows (version 24.0; IBM, Armonk, NY, USA).
R E S U L T S
At baseline, patients randomized to paricalcitol and placebo had similar age, gender and clinical characteristics. The eGFR tended to be higher (P ¼ 0.06) and FGF23 lower (P ¼ 0.07) in the paricalcitol arm as compared with patients in the placebo arm (Table 1) . Serum calcium and phosphate, 25-OH vitamin D, 1,25-OH vitamin D and PTH were similar in the two groups. As detailed in the PENNY study [7] , the use of angiotensinconverting enzyme inhibitors, sartans, hypoglicemizing agents, statins and proton-pump inhibitors were quite similar in the two study arms. However, calcium carbonate was more frequently prescribed to patients on placebo (22.7%) than to those in the paricalcitol arm (0%; P ¼ 0.003). As shown in Supplementary data Figure S1 , the distributions of adiponectin and FGF23 in the whole study cohort at baseline were skewed to the right.
Effect of paricalcitol and placebo treatment on adiponectin and FGF23
After the 12-week treatment, paricalcitol suppressed PTH and 1,25-OH vitamin D produced a modest increase in serum calcium and phosphate while no change in these parameters was observed in the placebo arm (see Supplementary data, Table S1 and [7] ).
Paricalcitol treatment produced a marked increase in serum FGF23 {baseline: 73 pg/mL [95% confidence interval (CI) 60-86]; 12th week: 180 pg/mL (95% CI 108-251)} while placebo did not modify FGF23 levels [baseline: 143 pg/mL (95% CI 38-247); 12th week: 122 pg/mL (95% CI 57-188); between-arms difference, g 2 ¼ 0.34; P < 0.001]. Serum adiponectin levels in response to treatments [placebo, baseline: 15.6 mg/mL (95% CI 13.3-17.9), 12th week: 15.7 mg/mL (95% CI 13.4-17.9); paricalcitol, baseline: 15.1 mg/mL (95% CI 12.3-17.8), 12th week: 14.5 mg/mL (95% CI 11.6-17.5)] did not show any difference between the two study arms (between-arms difference, g 2 ¼ 0.015; P ¼ 0.26).
Interaction of adiponectin with the FGF23 response to VDR activation
The FGF23 changes between the baseline and 12-week measurements across baseline adiponectin quartiles in the two study arms are shown in Figure 1 . In the placebo arm, no difference in FGF23 changes were noted among adiponectin quartiles (P ¼ 0.49). In contrast, in the paricalcitol arm, the median FGF23 response to this treatment was substantially higher (P ¼ 0.009) in the fourth adiponectin quartile [122 pg/mL (IQR 54-186)] than in the other quartiles (first quartile: 52.0 pg/mL, from 9 to 91 pg/ mL; second quartile: 24.2 pg/mL, from À5.7 to 141.0 pg/mL; third quartile: 31.0 pg/mL; from 13.5 to 78.2 pg/mL). This phenomenon suggested that high adiponectin levels amplify the FGF23 response to VDR activation by paricalcitol. Accordingly, formal interaction analysis in a model adjusting for baseline FGF23, eGFR and calcium carbonate treatment confirmed that baseline adiponectin actually modifies the FGF23 response to paricalcitol treatment (P ¼ 0.009). Of note, no similar interaction was found by other baseline variables on the FGF23 response to paricalcitol/ placebo for the full series of variables listed in Table 1 . Then we tested the hypothesis that dynamic changes in serum adiponectin levels following the study treatments modify the FGF23 response to the same treatments. Accordingly, this analysis revealed an even stronger effect modification by serum adiponectin on the same outcome measure (Figure 2) . Indeed, the estimated difference in serum FGF23 between paricalcitol-and placebo-treated patients rose progressively from 124 pg/mL (no change in adiponectin levels, i.e. the 0 point on the graph) along with increasing fluctuations in serum adiponectin, achieving the maximum rise (392 pg/mL) in patients with a 10 lg/mL increase in serum adiponectin (see Figure 2) . Conversely, the difference in serum FGF23 between the two study arms showed a gradual decline along with decreasing changes in serum adiponectin levels (P for effect modification ¼ 0.003) (Figure 2) . Furthermore, in keeping with findings described above for the static interaction, this dynamic interaction was specific because, again, no effect modification was noted for the FGF23 response to study treatments by the variables listed in Table 1 .
Relationship between adiponectin and FGF23
At baseline, i.e. before the application of the study interventions (placebo/paricalcitol), there was a significant relationship between circulating FGF23 and serum adiponectin (r ¼ 0.21, P ¼ 0.046) in the whole study population (n ¼ 88) (Figure 3, left  panel) . An adjusted and weighted regression analysis including baseline serum adiponectin and FGF23 as well as the same variables after 12 weeks of treatment, fully confirmed this relationship (b ¼ 0.22, P ¼ 0.003) (Figure 3, right panel) .
D I S C U S S I O N
In a double-blind, placebo-controlled randomized clinical trial testing the effects of the VDR activator paricalcitol in CKD patients, we found a consistent interaction of adiponectin with the FGF23 response to VDR activation by paricalcitol. Furthermore, in an adjusted global analysis encompassing all measurements of adiponectin and FGF23 across the trial, these two biomarkers were interrelated independent of the eGFR and other factors. Overall, findings in this study extend to CKD observations in genetically engineered mice models showing that adiponectin can modify FGF23 levels. The biologically active form of vitamin D promotes adipogenesis and influences the expression of typical adipocyte genes including the uncoupling protein genes [16] . Knockout mice for the nuclear VDR show an increase in energy expenditure and a loss of fat mass. Conversely, mice with VDR gene overexpression are obese [16] . With this knowledge, Rutkowski et al. [3] recently showed that ablation of the adiponectin gene generates a phenotype with a marked suppression of FGF23 levels in mice. Even though FGF23 levels were similar in the adiponectin knockout mice and in mice overexpressing this protein, these latter mice exhibited a substantially enhanced FGF23 response to phosphate load as compared with knockout and wild-type mice, revealing a direct correlation between adiponectin and FGF23 levels across these models [3] . Since the interrelationships between vitamin D, fat mass, adiponectin and FGF23 described so far in humans [12, 13, 17, 18] are merely descriptive in nature, no mechanistic inference can be made on these relationships in man. The issue clearly demands specific studies in healthy and disease states, including CKD, aimed at testing the effect of VDR activation on adiponectin and FGF23 levels and other interventions that may influence the reciprocal links among these factors. We have therefore investigated these relationships in specifically designed analyses in the database of a clinical trial testing the effects of paricalcitol in CKD patients, the PENNY trial [7] . In brief, on the basis of experimental data in genetically engineered mice models [3] , we hypothesized that adiponectin is not only related to FGF23 but also that it modulates the FGF23 response to VDR activation. Accordingly, we found that the FGF23 increase in response to paricalcitol was amplified in patients in the fourth baseline adiponectin quartile as compared with other quartiles. Furthermore, in an analysis considering adiponectin dynamically (adiponectin fluctuations after the study interventions), we observed that the betweentreatments difference in FGF23 levels was progressively higher across increasing serum adiponectin levels and progressively lower across declining levels of this adipokine. Along with our working hypothesis, we also found that adiponectin and FGF23 were weakly but significantly (P ¼ 0.003) related to each other independent of the GFR and other potential confounders. Overall, our findings in CKD patients are compatible with the hypothesis that both background adiponectin levels and dynamic changes in adiponectin after VDR activation have important modulatory effects on the FGF23 response to this treatment.
FIGURE 2:
Interaction between serum adiponectin changes and the difference in serum FGF23 levels between paricalcitol-and placebotreated patients (see the text for the description of this interaction). The continuous line represents the shape of the difference in FGF23 changes between paricalcitol-treated and untreated patients throughout serum adiponectin changes and the dotted lines are the corresponding 95% CIs. In the background, the distribution of adiponectin changes is plotted and the number of patients corresponding to each column of the histogram is reported on the right scale. Several limitations in this study should be acknowledged. First, rather than being a secondary, pre-planned analysis of the PENNY trial, this study was stimulated post hoc by experimental studies in animal models [3] . Second, we could focus only on the influence of adiponectin on the FGF23 response to VDR activation, thus we did not include detailed observations on physiologically relevant outcome measures related to these biomarkers, e.g. the FGFG23 co-factor a-Klotho, serum and urinary phosphate and calcium or parameters of glucose metabolism. Third, even though adiponectin and FGF23 were interrelated independent of eGFR and other factors, the possibility of residual confounding remains substantial when studying variables that are inherently associated with the GFR [19] , as is the case for adiponectin and FGF23. However, the fact that we performed our analyses using the entire database of the PENNY trial with no missing value of the key variables considered in the study is a strength. The robustness of the interactions between adiponectin and FGF23 is another strength, as it is the specificity of the same interactions that were restricted to adiponectin only.
In conclusion, in a post hoc analysis of the PENNY trial, we observed consistent interactions between adiponectin and the FGF23 response to VDR activation as well as an independent adiponectin-FGF23 relationship. Clinical studies including meaningful clinical outcome measures and interventions other than VDR activation are needed to confirm and extend the relevance of the findings in the present study.
S U P P L E M E N T A R Y D A T A
Supplementary data are available at ndt online.
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